TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01067508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiji Water
Description: Participants are asked to drink one liter of this silicon-rich water daily for three months.
Study: NCT00975702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC by Inflation of Pneumatic Tourniquet
Description: Pneumatic tourniquets will be placed on both lower extremities in all deceased donor subjects. In the RIPC group the tourniquets will be inflated sequentially for 10 min each followed by deflation, approximately, 30-60 min prior to aortic crossclamping and organ perfusion.
Study: NCT03917719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edasalonexent
Description: 100 mg/kg/day
Study: NCT02528500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis
Description: Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
Study: NCT02683616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous Positive Airway Pressure in cases of moderate/severe OSA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous Positive Airway Pressure in cases of moderate/severe OSA
Study: NCT01763476

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel-coated balloon angioplasty
Description: plain balloon angioplasty followed by paclitaxel-coated balloon angioplasty of the target lesion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel-coated balloon angioplasty
Description: plain balloon angioplasty followed by paclitaxel-coated balloon angioplasty of the target lesion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: atherectomy
Description: atherectomy (TurboHawk, ev3) followed by paclitaxel-coated balloon angioplasty of the target lesion
Study: NCT02179528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study: NCT01389648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre Operative
Description: Pre operative chest physiotherapy treatment
Study: NCT02919488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Condition
Description: A bout of exercise in the evening followed by high-sugar meal consumption the following morning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: Rest in the evening followed by high-sugar meal consumption the following morning
Study: NCT03377010

Intervention type: OTHER
Intervention: Dietary intake -Food Frequency Questionnaire
Description: Dietary intake will be assessed using 2014 full-length food frequency questionnaire. The Block 2014 questionnaire combines a full-length food frequency questionnaire with a brief physical activity screening tool. The food and beverage list includes 127 items in the past 1 month, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.

Intervention type: OTHER
Intervention: Receptivity to Participating in Diet Interventions
Description: Study participants will rate their interest in learning more about dietary interventions to stay healthy using items developed specifically for this study. The items will be rated on a 3-point Likert-type scale from 3 (extremely interested) to 1 (not at all interested).
Study: NCT02423434

Intervention type: OTHER
Intervention: Exposure: Corneal nerve fibre morphology by the CCM Procedure
Description: CCM is a non-invasive method for direct visualization of corneal nerve fibers. Previous research work has confirmed that corneal nerves status correlates with both small and large fibre damage as assessed by quantitative sensory testing and nerve conduction.~In the current trial subjects will undergo a bilateral examination of the Bowman's layer of the cornea using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine their corneal nerve fiber length, corneal nerve fiber density, corneal nerve branch density, and the tortuosity coefficient. Topical anaesthetic and a viscous gel medium will be applied to the eye, which will create a visual gel bridge between the cornea and the sterile single-use cap on the microscope objective lens. After the interface between the corneal epithelium and Bowman's layer is identified, batches of images will be taken and the most technically sound images will be identified and analyzed.
Study: NCT03535038

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Inferior vena cava (IVC) diameter using USG
Description: IVC diameter is measured from the distal of right hepatic pain and inferior vena cava meeting point using Philips En Visor C USG.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vascular pedicle width (VPW)
Description: VPW is measured by drawing a line from the left subclavian artery exit point from aorta perpendicular to the point where superior vena cava crosses with right bronchi.
Study: NCT02569411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: money
Study: NCT04791683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sexaul counseling
Description: Sexual counseling includes interviews about sexual problems in couples who are in the process of infertility treatment and suggestions for solving these problems.
Study: NCT01226355

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent
Description: NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System is manufactured by Medfavour (Beijing) Medical Co., Ltd.~Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System is manufactured by Medfavour (Beijing) Medical Co., Ltd.~Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
Study: NCT02276235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catgut embedding group
Description: An extensive form of acupuncture that involves weekly infixing self-absorptive chromic catgut sutures into acupoints with a specialised needle under antiseptic precautions. The catgut then stimulate those points over a long period. The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger with chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham catgut embedding group
Description: The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)
Study: NCT01928108

Intervention type: BEHAVIORAL
Intervention: iPhone Application
Description: The iPhone application waterlogged will be used by participants using and iPhone cellular device. This application will be used to track daily fluid intake for 1 week.
Study: NCT04089410

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of Cardiorespiratory Fitness
Description: An assessment of exercise tolerance and cardiorespiratory fitness (ET, CRF) is carried out with the use of Cardiopulmonary Exercise Test - CPET). Testing is carried out using a gas analyzer and an Intertrack treadmill. Evaluation of gas exchange parameters conducted according to a given program - Cardiopulmonary load testing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Autonomic Balance, Orthostatic and Hypoxic tolerance
Description: 1. Evaluation of Autonomic balance is assesed using Heart Rate Variability (HRV) analysis. The HRV test relies on a 5-min RR interval (time in milliseconds between two R waves of the electrocardiogram complex) recorded at rest for 5 min supine (SU) followed of 5 min resting time. Measurement of the interval duration between two R waves of the cardiac electrical activity are performed with a HR monitor.~2. Orthostatic tolerance is assessed after ANS balance assessment by HRV analysis to continue RR intervals registration for 3 min after participant was asked to stand up taking a vertical position near the couch.~3. The individual sensitivity to hypoxia is determined by conducting a 10-minute hypoxic test (HT) - breathing through a facial mask by a gas mixture with 11% of O2, with minute-by-minute monitoring of HR and hemoglobin saturation by oxygen (SaO2). Arterial blood pressure is recorded before and after HT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autonomic Balance, Orthostatic and Hypoxic tolerance
Description: 1. Evaluation of Autonomic balance is assesed using Heart Rate Variability (HRV) analysis. The HRV test relies on a 5-min RR interval (time in milliseconds between two R waves of the electrocardiogram complex) recorded at rest for 5 min supine (SU) followed of 5 min resting time. Measurement of the interval duration between two R waves of the cardiac electrical activity are performed with a HR monitor.~2. Orthostatic tolerance is assessed after ANS balance assessment by HRV analysis to continue RR intervals registration for 3 min after participant was asked to stand up taking a vertical position near the couch.~3. The individual sensitivity to hypoxia is determined by conducting a 10-minute hypoxic test (HT) - breathing through a facial mask by a gas mixture with 11% of O2, with minute-by-minute monitoring of HR and hemoglobin saturation by oxygen (SaO2). Arterial blood pressure is recorded before and after HT.
Study: NCT01928108

Intervention type: BEHAVIORAL
Intervention: Android Application
Description: The Android application water my body will be used by participants using an Android cellular device. This application will be used to track daily fluid intake for 1 week.
Study: NCT00059215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel (CS-747)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel (CS-747)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel (CS-747)
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Administered orally
Study: NCT02042495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT00666133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpringFusor Pump
Description: Women in Group I (Springfusor® arm) will receive loading and maintenance doses of magnesium sulfate administered via an IV infusion administered with the Springfusor pump, a simple, inexpensive flow-controlled pump system.
Study: NCT00932529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion
Study: NCT01153763

Intervention type: DRUG
Group type: OTHER
Intervention: GSK2118436
Description: Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
Study: NCT03766087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: decompressive craniectomy
Description: decompressive craniectomy is decompression at the supratentorial level that is achieved by removing part of the skull and by making an opening, in the dura mater (with or without plastic surgery), without compromising the venous sinus.
Study: NCT03357809

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection
Description: Mucosectomy performed at day 1. Endoscopic mucosal resection (EMR) and or endoscopic submucosal dissection (ESD), is at least 3 cm long. The mucosal resection is carried out along the side of the small curvature of the stomach, in order to preserve a valve of the cardia at the level of the large curvature of the stomach.~A coloured solution is injected into the submucosa following markers. The correct submucosal injection is confirmed by the lifting of the mucosal surface. A submucosal dissection is carried out using the dual knife. The mucosectomy is repeatedly performed until the mucosal zone is completely resected. The choice of the resection technique will depend on the anatomy of the patient.
Study: NCT00675974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jobst Pressure Garment
Description: Pressure garment therapy for 18 months post burn injury. May be Jobst pressure garment or Medical Z pressure garment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Z pressure garment
Description: Pressure garment to be worn for 18 months post burn. May be Jobst pressure garment or Medical Z pressure garment.
Study: NCT05228444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CircadianCare
Description: enhancing circadian rhythmicity through an assessment of the patient's specific circadian features/needs and an ad hoc, personalized light-dark, meal and activity schedule to cover the whole of the inpatient stay.
Study: NCT03716232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metallic stent
Description: All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..~- Stent will be extracted endoscopically after 6 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple plastic stents
Description: Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.~Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion.
Study: NCT03700476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg will be given every 3 weeks for 12 cycles, started on day 1 of induction chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiotherapy
Description: Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy
Description: Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
Study: NCT03213613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Attention Training
Description: The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Active Control
Description: Participants in the expectancy-matched active control group will play a visuo-spatial iPad game, in which players use their finger to move an object to different successive square platforms. Expectancy matching to the adaptive attention training was pre-confirmed in 121 participants (18-20 years of age), using targeted surveys on MTurk about their expectations of either training exposure on our specific outcome measures. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose Adaptive Attention Training
Description: Participants in the low-dose training group will play a reduced number of sessions as the Adaptive Attention Training group. Specifically, they will train for two 30-minute sessions at the start and middle of a six-week period. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
Study: NCT01657448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine and Methylthioninium chloride
Description: • Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenazopyridine
Description: • Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
Study: NCT02648412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: bolus 1 mg/kg
Study: NCT04089410

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychological Testing
Description: 1. Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36), which is a self-completed quantity of health-related QoL.~2. Participants are asked to complete the Pittsburgh Sleep Quality Index (PSQI), a retrospective self-report measure assessing their quality of sleep during the last three weeks preceding the study.~3. Anxiety level is estimated by using State and Trait Anxiety Scales (SA and TA) developed by Ch. Spielberger~4. Subjective Ratings of Thermosensation and Pain.Participants rate their comfort, thermosensation, and pain by fixing results in visual-analogous scale (VAS) while passing each of HFT treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychological Testing
Description: 1. Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36), which is a self-completed quantity of health-related QoL.~2. Participants are asked to complete the Pittsburgh Sleep Quality Index (PSQI), a retrospective self-report measure assessing their quality of sleep during the last three weeks preceding the study.~3. Anxiety level is estimated by using State and Trait Anxiety Scales (SA and TA) developed by Ch. Spielberger~4. Subjective Ratings of Thermosensation and Pain.Participants rate their comfort, thermosensation, and pain by fixing results in visual-analogous scale (VAS) while passing each of HFT treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Measurement of Blood Markers
Description: Periferal venous blood (10 ml) sumples of the fastest (overnight fast) study subjects are withdrawn by a qualified laboratory technician via aseptic technique from the antecubital vein in the sitting position, using sterile needles and are collected. Serum BDNF, HGH, HSPs (60, 70, 90) concentrations are determined.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of Blood Markers
Description: Periferal venous blood (10 ml) sumples of the fastest (overnight fast) study subjects are withdrawn by a qualified laboratory technician via aseptic technique from the antecubital vein in the sitting position, using sterile needles and are collected. Serum BDNF, HGH, HSPs (60, 70, 90) concentrations are determined.
Study: NCT03230214

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR for bacterial translocation
Description: samples taken from the blood and ascites of patients to search for bacterial DNA
Study: NCT02648412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tetanic stimulations of incremental intensities
Description: 10-20-30-40-60 milliamps on the patient's left forearm
Study: NCT04097756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX-039 tablets
Description: orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, or study termination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX-039 tablets
Description: orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
Study: NCT02477085

Intervention type: OTHER
Intervention: all women with an induced labor
Description: all women who have an induced labor